Skip to main content

Clinical trial Checkmate 142

CA209-142 A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer. Checkmate 142

Cancers
Organ Colon
Trial status Trial closed for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 2
Academic trial Non
Sponsor BMS - Bristol Myers Squibb int.
EudraCT Identifier 2013-003939-30
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02060188
Inclusion criteria metastatic RECIST 1.1
Last update